Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:EXEL
- CUSIP: 30161Q10
- Web: www.exelixis.com
Capitalization:- Market Cap: $8.1962 billion
- Outstanding Shares: 292,512,000
Average Prices:- 50 Day Moving Avg: $24.25
- 200 Day Moving Avg: $21.64
- 52 Week Range: $8.75 - $28.23
P/E:- Trailing P/E Ratio: 1290.95
- Foreward P/E Ratio: 49.29
- P/E Growth: 3.31
Sales & Book Value:- Annual Revenue: $256.91 million
- Price / Sales: 30.87
- Book Value: $0.41 per share
- Price / Book: 66.12
Profitability:- EBIDTA: $43.6 million
- Net Margins: 1.37%
- Return on Equity: 126.82%
- Return on Assets: 3.15%
Debt:- Current Ratio: 2.31%
- Quick Ratio: 2.30%
Misc:- Average Volume: 4.29 million shs.
- Beta: 1.88
- Short Ratio: 3.04
Frequently Asked Questions for Exelixis (NASDAQ:EXEL)
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) released its quarterly earnings data on Monday, May, 1st. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.06. The company earned $80.90 million during the quarter, compared to the consensus estimate of $65.23 million. Exelixis had a net margin of 1.37% and a return on equity of 126.82%. Exelixis's revenue for the quarter was up 425.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. View Exelixis' Earnings History.
When will Exelixis make its next earnings announcement?
Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?
11 brokers have issued 12 month price objectives for Exelixis' stock. Their predictions range from $8.00 to $33.00. On average, they expect Exelixis' share price to reach $19.80 in the next year. View Analyst Ratings for Exelixis.
What are analysts saying about Exelixis stock?
Here are some recent quotes from research analysts about Exelixis stock:
- 1. Cann analysts commented, "Exelixis, Inc. announced today a settlement of the company’s dispute with Genentech, a member of the Roche Group, concerning the parties’ collaboration for the development and commercialization of Cotellic (cobimetinib). As part of the settlement, effective July 1, 2017, the companies have amended the existing Collaboration Agreement to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016." (7/20/2017)
- 2. According to Zacks Investment Research, "Exelixis received a major boost with the FDA approval of Cabometyx tablets in Apr 2016. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters in 2017. The sequential increase in Cabometyx sales is also a positive. Moreover, Cabometyx was also approved in the EU. Meanwhile, Exelixis is developing cabozantinib in a broad development program and plans to file a supplemental New Drug Application (sNDA) in the third quarter of 2017 for advanced RCC. A potential label expansion will further boost sales. Exelixis also has collaborations with Bristol-Myers and Roche on the development of cabozantinib in combination with immunotherapy agents. Exelixis’ share price outperformed the Zacks classified Biomedical and Genetics industry year to date. However, the company is heavily dependent on Cabometyx for growth now. Operating expenses are also projected to increase." (7/11/2017)
Are investors shorting Exelixis?
Exelixis saw a decline in short interest in the month of June. As of June 30th, there was short interest totalling 15,465,148 shares, a decline of 12.5% from the June 15th total of 17,681,775 shares. Based on an average daily volume of 7,594,749 shares, the days-to-cover ratio is presently 2.0 days. Currently, 5.5% of the company's stock are sold short.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include BIOVERATIV INC (BIVV), TESARO (TSRO), Kite Pharma (KITE), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), China Biologic Products (CBPO), AveXis (AVXS), Prothena Corporation PLC (PRTA), Axovant Sciences (AXON), Spark Therapeutics (ONCE) and Sarepta Therapeutics (SRPT).
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder
- Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director
- Christopher J. Senner, Chief Financial Officer, Executive Vice President
- Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer
- Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer
- Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary
- Patrick Haley, Senior Vice President - Commercial
- Charles M. Cohen Ph.D., Independent Director
- Carl B. Feldbaum Esq., Independent Director
- Alan M. Garber M.D. Ph.D., Independent Director
Who owns Exelixis stock?
Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Meditor Group Ltd (6.92%), Acadian Asset Management LLC (0.54%), Handelsbanken Fonder AB (0.12%), Russell Investments Group Ltd. (0.09%), Spark Investment Management LLC (0.05%) and Bank of Montreal Can (0.04%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Who sold Exelixis stock? Who is selling Exelixis stock?
Exelixis' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Spark Investment Management LLC, Bank of Montreal Can, Insight Capital Research & Management Inc., Cutler Capital Management LLC, Klingenstein Fields & Co. LLC and Plancorp LLC. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Who bought Exelixis stock? Who is buying Exelixis stock?
Exelixis' stock was acquired by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Creative Planning, Handelsinvest Investeringsforvaltning, Capstone Asset Management Co., Public Employees Retirement Association of Colorado, Great West Life Assurance Co. Can, First Quadrant L P CA and Meeder Asset Management Inc.. View Insider Buying and Selling for Exelixis.
How do I buy Exelixis stock?
Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of Exelixis stock can currently be purchased for approximately $27.11.
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Exelixis (NASDAQ:EXEL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.64) |
| Consensus Price Target: | $19.80 (26.98% downside) |
Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/27/2017 | William Blair | Reiterated Rating | Outperform | | Low |  |
| 7/20/2017 | Cann | Reiterated Rating | Hold | | Low | |
| 7/13/2017 | SunTrust Banks, Inc. | Initiated Coverage | Buy -> Buy | $33.00 | Medium | |
| 6/12/2017 | Oppenheimer Holdings, Inc. | Initiated Coverage | Hold | | Low | |
| 3/31/2017 | Needham & Company LLC | Initiated Coverage | Buy -> Buy | $28.00 | Medium | |
| 3/16/2017 | CIBC | Initiated Coverage | Market Perform -> Market Perform | | High | |
| 2/28/2017 | Stifel Nicolaus | Downgrade | Buy -> Hold | $22.00 | N/A | |
| 1/24/2017 | Cowen and Company | Reiterated Rating | Outperform | | N/A | |
| 11/3/2016 | Deutsche Bank AG | Initiated Coverage | Buy | $17.00 | N/A | |
| 10/10/2016 | Piper Jaffray Companies | Upgrade | Neutral -> Overweight | | N/A | |
| 10/7/2016 | Leerink Swann | Reiterated Rating | Positive | $15.00 | N/A | |
| 9/28/2016 | S&P Equity Research | Boost Price Target | | $13.41 -> $15.57 | N/A | |
(Data available from 7/28/2015 forward)
Earnings History for Exelixis (NASDAQ:EXEL)Earnings History by Quarter for Exelixis (NASDAQ EXEL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | | | | | | | |
| 5/1/2017 | Q1 2017 | ($0.01) | $0.05 | $65.23 million | $80.90 million | View | Listen | |
| 2/27/2017 | Q416 | ($0.01) | $0.12 | $64.88 million | $77.58 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.13) | ($0.04) | $43.15 million | $62.19 million | View | N/A | |
| 8/3/2016 | Q216 | ($0.27) | ($0.16) | $16.76 million | $36.25 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.25) | ($0.27) | $9.11 million | $15.40 million | View | Listen | |
| 2/29/2016 | Q415 | ($0.22) | ($0.19) | $8.16 million | $9.94 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.20) | ($0.22) | $9.08 million | $9.85 million | View | Listen | |
| 8/11/2015 | Q215 | ($0.21) | ($0.22) | $8.69 million | $8.00 million | View | Listen | |
| 4/30/2015 | Q115 | ($0.24) | ($0.18) | $8.08 million | $9.40 million | View | Listen | |
| 2/24/2015 | Q414 | ($0.31) | ($0.30) | $7.50 million | $7.35 million | View | Listen | |
| 11/4/2014 | Q314 | ($0.37) | ($0.32) | $6.77 million | $6.30 million | View | Listen | |
| 7/31/2014 | Q214 | ($0.39) | ($0.38) | $5.66 million | $6.56 million | View | Listen | |
| 5/1/2014 | Q114 | ($0.37) | ($0.39) | $6.11 million | $4.90 million | View | Listen | |
| 2/20/2014 | Q413 | ($0.38) | ($0.38) | $5.71 million | $4.34 million | View | Listen | |
| 10/30/2013 | Q313 | ($0.37) | ($0.36) | $5.55 million | $5.50 million | View | Listen | |
| 8/6/2013 | Q2 2013 | ($0.30) | ($0.34) | $6.55 million | $11.90 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.29) | ($0.24) | $5.33 million | $9.70 million | View | Listen | |
| 2/21/2013 | Q4 2012 | ($0.24) | ($0.28) | $9.46 million | $7.80 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.30) | ($0.20) | $9.22 million | $13.30 million | View | N/A | |
| 8/2/2012 | | ($0.27) | ($0.25) | | | View | N/A | |
| 5/3/2012 | | ($0.19) | ($0.18) | | | View | N/A | |
| 10/27/2011 | | $0.57 | $0.60 | | | View | N/A | |
| 8/4/2011 | | ($0.17) | ($0.16) | | | View | N/A | |
| 5/3/2011 | | ($0.19) | ($0.24) | | | View | N/A | |
| 2/22/2011 | | ($0.21) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Exelixis (NASDAQ:EXEL)2017 EPS Consensus Estimate: $0.06
2018 EPS Consensus Estimate: $0.32
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($0.03) | $0.01 | ($0.01) |
| Q2 2017 | 4 | $0.01 | $0.03 | $0.02 |
| Q3 2017 | 4 | $0.00 | $0.03 | $0.02 |
| Q4 2017 | 4 | $0.00 | $0.04 | $0.03 |
| Q1 2018 | 1 | $0.06 | $0.06 | $0.06 |
| Q2 2018 | 1 | $0.07 | $0.07 | $0.07 |
| Q3 2018 | 1 | $0.09 | $0.09 | $0.09 |
| Q4 2018 | 1 | $0.10 | $0.10 | $0.10 |
(Data provided by Zacks Investment Research)
Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Exelixis (NASDAQ:EXEL)Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 80.85%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/30/2017 | Patrick J. Haley | Insider | Sell | 5,000 | $18.46 | $92,300.00 | |
| 5/15/2017 | Carl B Feldbaum | Director | Sell | 32,988 | $21.58 | $711,881.04 | |
| 5/10/2017 | Michael Morrissey | Insider | Sell | 211,300 | $21.87 | $4,621,131.00 | |
| 5/9/2017 | Michael Morrissey | CEO | Sell | 100,000 | $21.69 | $2,169,000.00 | |
| 5/8/2017 | Michael Morrissey | CEO | Sell | 11,300 | $21.81 | $246,453.00 | |
| 5/5/2017 | Michael Morrissey | Insider | Sell | 259,149 | $22.24 | $5,763,473.76 | |
| 5/1/2017 | Gisela Schwab | CMO | Sell | 89,910 | $23.01 | $2,068,829.10 | |
| 4/3/2017 | Vincent T Marchesi | Director | Sell | 10,000 | $21.30 | $213,000.00 | |
| 3/31/2017 | Jack L Wyszomierski | Director | Sell | 5,150 | $21.57 | $111,085.50 | |
| 3/27/2017 | Jeffrey Hessekiel | EVP | Sell | 6,884 | $21.02 | $144,701.68 | |
| 3/22/2017 | Jeffrey Hessekiel | EVP | Sell | 23,787 | $20.54 | $488,584.98 | |
| 3/20/2017 | Stelios Papadopoulos | Director | Sell | 10,000 | $21.66 | $216,600.00 | |
| 3/13/2017 | Charles Cohen | Director | Sell | 10,000 | $21.82 | $218,200.00 | |
| 3/10/2017 | Vincent T Marchesi | Director | Sell | 40,000 | $21.98 | $879,200.00 | |
| 3/6/2017 | Michael Morrissey | Insider | Sell | 200,000 | $22.72 | $4,544,000.00 | |
| 3/3/2017 | Christopher J. Senner | CFO | Sell | 11,000 | $22.80 | $250,800.00 | |
| 3/2/2017 | George Poste | Director | Sell | 76,250 | $22.53 | $1,717,912.50 | |
| 1/3/2017 | Peter Lamb | EVP | Sell | 70,000 | $14.65 | $1,025,500.00 | |
| 12/16/2016 | Carl B. Feldbaum | Director | Sell | 25,000 | $17.03 | $425,750.00 | |
| 12/9/2016 | Alan M. Garber | Director | Sell | 7,832 | $16.90 | $132,360.80 | |
| 12/7/2016 | George A. Scangos | Director | Sell | 204,894 | $17.81 | $3,649,162.14 | |
| 12/5/2016 | George A. Scangos | Director | Sell | 204,718 | $17.81 | $3,646,027.58 | |
| 12/1/2016 | Gisela Schwab | Insider | Sell | 22,000 | $16.73 | $368,060.00 | |
| 12/1/2016 | Peter Lamb | EVP | Sell | 70,000 | $16.66 | $1,166,200.00 | |
| 8/4/2016 | Gisela Schwab | Insider | Sell | 42,338 | $11.00 | $465,718.00 | |
| 5/11/2016 | Lance Willsey | Director | Buy | 60,000 | $4.97 | $298,200.00 | |
| 5/9/2016 | Lance Willsey | Director | Buy | 40,000 | $4.97 | $198,800.00 | |
| 12/11/2015 | Lance Willsey | Director | Buy | 100,000 | $4.89 | $489,000.00 | |
| 10/16/2015 | Peter Lamb | EVP | Sell | 51,549 | $5.80 | $298,984.20 | |
| 10/13/2015 | Peter Lamb | EVP | Sell | 600 | $5.80 | $3,480.00 | |
| 10/12/2015 | Peter Lamb | EVP | Sell | 300,276 | $5.84 | $1,753,611.84 | |
| 9/17/2014 | Vincent T Marchesi | Director | Buy | 20,000 | $1.71 | $34,200.00 | |
| 8/29/2013 | Lance Willsey | Director | Buy | 10,000 | $5.15 | $51,500.00 | |
| 12/20/2012 | Vincent T Marchesi | Director | Buy | 4,000 | $4.68 | $18,720.00 | |
| 12/19/2012 | Vincent T Marchesi | Director | Buy | 6,000 | $4.72 | $28,320.00 | |
| 12/10/2012 | Gisela Schwab | EVP | Buy | 25,000 | $4.39 | $109,750.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Exelixis (NASDAQ:EXEL)
Latest Headlines for Exelixis (NASDAQ:EXEL)
| Source: |
|
| Date | Headline |
|---|
 | Exelixis, Inc. (NASDAQ:EXEL) Rating Reiterated by William Blair
www.americanbankingnews.com - July 27 at 5:14 PM |
 | Opinion: Three biotech companies to watch ahead of earnings - MarketWatch
www.marketwatch.com - July 25 at 6:44 PM |
 | Technical Snapshots for These Biotech Stocks -- Exelixis, Celldex Therapeutics, Clovis Oncology, and Geron
www.bizjournals.com - July 24 at 8:00 PM |
 | What's in the Cards for Exelixis (EXEL) in Q2 Earnings?
www.zacks.com - July 24 at 8:00 PM |
 | What's in the Cards for Exelixis (EXEL) in Q2 Earnings?
finance.yahoo.com - July 24 at 7:59 PM |
| FY2019 Earnings Estimate for Exelixis, Inc. (NASDAQ:EXEL) Issued By Leerink Swann
www.americanbankingnews.com - July 24 at 11:30 AM |
| FY2018 EPS Estimates for Exelixis, Inc. Raised by Leerink Swann (NASDAQ:EXEL)
www.americanbankingnews.com - July 21 at 3:32 PM |
| FY2018 EPS Estimates for Exelixis, Inc. Lowered by William Blair (EXEL)
www.americanbankingnews.com - July 21 at 3:30 PM |
| William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)
finance.yahoo.com - July 21 at 3:17 PM |
| 2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't
finance.yahoo.com - July 21 at 3:17 PM |
 | Exelixis (EXEL), Genentech Reach Settlement in Dispute Regarding Companies' Collaboration Agreement for Cobimetinib
www.streetinsider.com - July 20 at 9:10 PM |
 | BRIEF-Exelixis announces settlement of dispute with Genentech
www.reuters.com - July 20 at 9:10 PM |
 | Exelixis Announces Settlement of Dispute with Genentech ... - Business Wire (press release)
www.businesswire.com - July 20 at 4:06 PM |
| Exelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for Cobimetinib
finance.yahoo.com - July 20 at 4:06 PM |
| Exelixis, Inc. (EXEL) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - July 20 at 11:36 AM |
 | Exelixis up 2% on settlement of cobimetinib collaboration spat with Genentech
seekingalpha.com - July 20 at 11:13 AM |
| Updates To Exelixis Thesis: Management Continues To Execute - Seeking Alpha
seekingalpha.com - July 17 at 7:26 PM |
| Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017
finance.yahoo.com - July 17 at 7:26 PM |
| Cramer's lightning round: This business is better than people think
finance.yahoo.com - July 17 at 7:26 PM |
| Exelixis, Inc. (EXEL) Forecasted to Earn Q2 2017 Earnings of $0.01 Per Share
www.americanbankingnews.com - July 17 at 7:46 AM |
| Exelixis, Inc. (EXEL) Now Covered by Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - July 16 at 5:14 PM |
 | Company Spotlight: Exelixis
www.rttnews.com - July 16 at 10:25 AM |
| Short Interest in Exelixis, Inc. (NASDAQ:EXEL) Declines By 12.5%
www.americanbankingnews.com - July 16 at 7:06 AM |
 | Company Spotlight: Exelixis - Nasdaq
www.nasdaq.com - July 14 at 5:04 PM |
| Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017? - Nasdaq
www.nasdaq.com - July 14 at 12:51 AM |
| Why Exelixis (EXEL) Could Be an Impressive Growth Stock - Yahoo Finance
finance.yahoo.com - July 13 at 7:48 PM |
| Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?
finance.yahoo.com - July 13 at 7:48 PM |
| Q2 2017 Earnings Forecast for Exelixis, Inc. Issued By William Blair (EXEL)
www.americanbankingnews.com - July 12 at 7:46 AM |
| Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx - Nasdaq
www.nasdaq.com - July 11 at 7:39 PM |
| Exelixis, Inc. (EXEL) Forecasted to Post FY2017 Earnings of $0.17 Per Share
www.americanbankingnews.com - July 11 at 10:06 AM |
| Exelixis, Inc. (EXEL) Rating Increased to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 10:04 AM |
 | Biotech Movers: Exelixis, Omeros, Inovio - TheStreet.com
www.thestreet.com - July 10 at 6:26 PM |
| Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
finance.yahoo.com - July 10 at 6:26 PM |
| Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals Corporation and Exelixis Inc.
finance.yahoo.com - July 10 at 6:26 PM |
| UK's advisor to NHS backs inclusion of Exelixis' Cabometyx for patients with advanced kidney cancer; shares up 1%
seekingalpha.com - July 10 at 1:27 PM |
| Bristol Myers launches late-stage study assessing combination of Opdivo or Opdivo/Yervoy with Exelixis' Cabometyx in kidney cancer
seekingalpha.com - July 10 at 10:50 AM |
| Exelixis: Great Stock, What's Next? - Seeking Alpha
seekingalpha.com - July 8 at 6:00 PM |
 | The Cabosun Shone on Exelixis in June, Sending Its Shares Up 32% - Motley Fool
www.fool.com - July 8 at 6:00 PM |
| This Biotech Finds Its Stride With Kidney Cancer Treatment
finance.yahoo.com - July 8 at 10:41 AM |
| $85.12 Million in Sales Expected for Exelixis, Inc. (EXEL) This Quarter
www.americanbankingnews.com - July 8 at 9:38 AM |
| Exelixis, Inc. (EXEL) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 7 at 10:52 AM |
| The Cabosun Shone on Exelixis in June, Sending Its Shares Up 32%
www.fool.com - July 7 at 8:34 AM |
| Analysts Expect Exelixis, Inc. (EXEL) Will Post Earnings of $0.03 Per Share
www.americanbankingnews.com - July 6 at 2:36 PM |
| Exelixis, Inc. (NASDAQ:EXEL) Upgraded to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - July 4 at 11:04 AM |
| Exelixis, Inc. (EXEL) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 2 at 4:58 PM |
| Acadia Pharmaceuticals: Biotech Stocks In Renewed Price Interest
seekingalpha.com - June 29 at 7:58 PM |
| Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness
finance.yahoo.com - June 29 at 7:58 PM |
| Short Interest in Exelixis, Inc. (EXEL) Drops By 8.1%
www.americanbankingnews.com - June 29 at 7:18 AM |
| Exelixis, Inc. Expected to Post Q2 2017 Earnings of $0.01 Per Share (EXEL)
www.americanbankingnews.com - June 28 at 7:32 AM |
| This Drugmaker Flirts With Breakout As Some Biotechs Rally
finance.yahoo.com - June 26 at 11:12 PM |
Exelixis (EXEL) Chart for Friday, July, 28, 2017
